

1 **A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS**  
2 **Administered via Different Routes and Doses (HVTN 127/HPTN 087)**

3  
4 Stephen R. Walsh <sup>1,2,\*</sup>, ‡, Cynthia L. Gay <sup>3,\*</sup>, Shelly T. Karuna <sup>4</sup>, Ollivier Hyrien <sup>4</sup>, Timothy  
5 Skalland <sup>4</sup>, Kenneth H. Mayer <sup>2,5</sup>, Magdalena E. Sobieszczyk <sup>6</sup>, Lindsey R. Baden <sup>1,2</sup>,  
6 Paul A. Goepfert <sup>7</sup>, Carlos del Rio <sup>8</sup>, Guiseppe Pantaleo <sup>9</sup>, Philip Andrew <sup>10</sup>, Carissa  
7 Karg <sup>4</sup>, Zonglin He <sup>4</sup>, Helen Lu <sup>4</sup>, Carmen A. Paez <sup>4</sup>, Jane A. G. Baumblatt <sup>11</sup>, Laura L.  
8 Polakowski <sup>11</sup>, Wairimu Chege <sup>11</sup>, Sophie Janto <sup>4</sup>, Xue Han <sup>4,⊕</sup>, Yunda Huang <sup>4</sup>, Julie  
9 Dumond <sup>12</sup>, Margaret E. Ackerman <sup>13</sup>, Adrian B. McDermott <sup>11</sup>, Britta Flach <sup>11</sup>, Estelle  
10 Piwowar-Manning <sup>14</sup>, Kelly Seaton <sup>15</sup>, Georgia D. Tomaras <sup>15</sup>, David C. Montefiori <sup>15</sup>,  
11 Lucio Gama <sup>11</sup>, John R. Mascola <sup>16,¶</sup>, for the HVTN 127/HPTN 087 Study Team

12  
13 <sup>1</sup> Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA  
14 <sup>2</sup> Harvard Medical School, Boston, MA  
15 <sup>3</sup> Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC  
16 <sup>4</sup> Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA  
17 <sup>5</sup> Fenway Institute, Boston, MA  
18 <sup>6</sup> Division of Infectious Diseases, Columbia University, New York, NY  
19 <sup>7</sup> University of Alabama at Birmingham, Birmingham, AL  
20 <sup>8</sup> Emory University School of Medicine and Ponce de Leon Center of the Grady Health  
21 System, Atlanta, GA  
22 <sup>9</sup> Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland  
23 <sup>10</sup> FHI 360, Durham, NC  
24 <sup>11</sup> Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD  
25 <sup>12</sup> Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC  
26 <sup>13</sup> Thayer School of Engineering, Dartmouth College, Hanover, NH  
27 <sup>14</sup> Johns Hopkins University, Baltimore, MD

28 <sup>15</sup> Department of Surgery and Duke Human Vaccine Institute, Duke University, Durham,  
29 NC

30 <sup>16</sup> Vaccine Research Center, National Institute of Allergy and Infectious Diseases,  
31 Bethesda, MD

32

33 \* These authors contributed equally.

34 ¶ Present Address: ModeX Therapeutics, Natick, MA

35 ⊕ Present Address: Atara Biotherapeutics, Thousand Oaks, CA

36

37 **Word count of text:** 5249

38 **Word Count of Abstract:** 471

39 **Running Title:** VRC07-523LS safety and PK

40

41 ‡**Corresponding Author:**

42 Dr. Stephen R. Walsh

43 Division of Infectious Diseases

44 Brigham & Women's Hospital

45 75 Francis Street, PBB-A-4

46 Boston, MA 02115

47 Telephone: +1-617-525-8418

48 Fax: +1-617-732-6829

49 E-mail: [swalsh@bwh.harvard.edu](mailto:swalsh@bwh.harvard.edu)

50

51 **Disclaimer:** This article was written by some authors [JAGB, LLP, WC, ABM, BF, LG,  
52 JCM] in their capacity as employees of the National Institutes of Health (NIH), but the  
53 views expressed herein do not necessarily represent those of the NIH.

54

55 **Abstract**

56

57 **Background:** Broadly neutralizing antibodies (bnAbs) are a promising approach for  
58 HIV-1 prevention. In the only bnAb HIV prevention efficacy studies to date, the Antibody  
59 Mediated Prevention (AMP) trials, a CD4-binding site targeting bnAb, VRC01,  
60 administered intravenously (IV), demonstrated 75% prevention efficacy against highly  
61 neutralization-sensitive viruses but was ineffective against less sensitive viruses.  
62 Greater efficacy is required before passively administered bnAbs become a viable  
63 option for HIV prevention; furthermore subcutaneous (SC) or intramuscular (IM)  
64 administration may be preferred. VRC07-523LS is a next-generation bnAb targeting the  
65 CD4-binding site and was engineered for increased neutralization breadth and half-life.

66 **Methods:** Participants were recruited between 02 February 2018 and 09 October 2018.  
67 124 healthy participants without HIV were randomized to receive five VRC07-523LS  
68 administrations via IV (T1: 2.5 mg/kg, T2: 5 mg/kg, T3: 20 mg/kg), SC (T4: 2.5 mg/kg,  
69 T5: 5 mg/kg) or IM (T6: 2.5 mg/kg or P6: placebo) routes at four-month intervals. Safety  
70 data were collected for 144 weeks following the first administration. VRC07-523LS  
71 serum concentrations were measured by ELISA after the first dose through Day 112 in  
72 all participants and by binding antibody multiplex assay (BAMA) thereafter in 60  
73 participants (10 per treatment group) through Day 784. Compartmental population  
74 pharmacokinetic (PK) analyses were conducted to evaluate the VRC07-523LS serum  
75 pharmacokinetics. Neutralization activity was measured in a TZM-bl assay and anti-drug  
76 antibodies (ADA) were assayed using a tiered bridging assay testing strategy.

77 **Results:** Injections were well-tolerated, with mild pain or tenderness reported commonly  
78 in the SC and IM groups, and mild to moderate erythema or induration reported  
79 commonly in the SC groups. Infusions were generally well-tolerated, with infusion  
80 reactions reported in 3 of 20 participants in the 20 mg/kg IV group. Peak geometric  
81 mean (GM) concentrations (95% confidence intervals) following the first administration  
82 were 29.0 µg/mL (25.2, 33.4), 58.5 µg/mL (49.4, 69.3), and 257.2 µg/mL (127.5, 518.9)  
83 in T1-T3 with IV dosing; 10.8 µg/mL (8.8, 13.3) and 22.8 µg/mL (20.1, 25.9) in T4-T5  
84 with SC dosing; and 16.4 µg/mL (14.7, 18.2) in T6 with IM dosing. Trough GM  
85 concentrations immediately prior to the second administration were 3.4 µg/mL (2.5, 4.6),  
86 6.5 µg/mL (5.6, 7.5), and 27.2 µg/mL (23.9, 31.0) with IV dosing; 0.97 µg/mL (0.65, 1.4)  
87 and 3.1 µg/mL (2.2, 4.3) with SC dosing, and 2.6 µg/mL (2.05, 3.31) with IM dosing.  
88 Peak VRC07-523LS serum concentrations increased linearly with the administered  
89 dose. At a given dose, peak and trough concentrations, as well as serum neutralization  
90 titres, were highest in the IV groups, reflecting the lower bioavailability following SC and  
91 IM administration. A single participant was found to have low titre ADA at a lone  
92 timepoint. VRC07-523LS has an estimated mean half-life of 42 days (95% CI: 40.5,  
93 43.5), approximately twice as long as VRC01.

94 **Conclusions:** VRC07-523LS was safe and well-tolerated across a range of doses and  
95 routes and is a promising long-acting bnAb for inclusion in HIV-1 prevention regimens.

96

97 **Trial Registration:** <http://www.clinicaltrials.gov/> Identifier: NCT03387150 (posted on 21  
98 December 2017)

99

100 **Potential Conflict of Interest:** SRW has conducted clinical trials funded by Janssen  
101 Vaccines, Moderna, Pfizer, Vir, Worcester HIV Vaccine, and Sanofi Pasteur, and serves  
102 on Independent Data Monitoring Committees for Janssen Vaccines and BioNTech;  
103 SRW's spouse is an employee of Regeneron Pharmaceuticals and may hold stock  
104 and/or stock options. CLG has received research support from Gilead and ViiV  
105 Healthcare and conducted clinical trials funded by Moderna and Novavax. MEA has  
106 received research support from Janssen, Be Bio, and Moderna.

107

108 **Funding:** US National Institutes of Health (NIH) [[www.nih.gov](http://www.nih.gov)] grants UM1 AI068614  
109 (STK, CK, CAP, SJ, GDT), UM1 AI068635 (OH, ZH, HL, YH), UM1 AI068618 (KS,  
110 GDT, DCM), UM1 AI069412 (SRW, LRB), UL1 RR025758 (LRB), P30 AI50410 (CLG),  
111 UM1 AI069423 (CLG), UM1 AI068619 (PA, JD), UM1 AI068617 (TS), UM1 AI068613  
112 (EPM), UM1 TR004406 (CLG). JAGB, LLP, and WC are/were Medical Officers with the  
113 National Institute of Allergy and Infectious Diseases (NIAID)/NIH and ABM, BF, LG, and  
114 JCM are/were Staff Scientists with NIAID/NIH. The funder had no other role in the study  
115 design, data collection and analysis, decision to publish, or preparation of the  
116 manuscript.

117

118 **Presented in part at:** HIV R4P 2021 Virtual (Abstract OA03.01), Cape Town, South  
119 Africa, January 2021; and IAS 2022 (Abstract PESUA14), Montréal, Canada, July 2022

120

121 **Details of the oversight body:** The Partners Human Research Committee of Brigham  
122 and Women's Hospital gave ethical approval of this work. The Centre Hospitalier  
123 Universitaire Vaudois Institutional Review Board of the Centre Hospitalier Universitaire  
124 Vaudois gave ethical approval of this work. The Fred Hutchinson Cancer Research  
125 Center Institutional Review Board gave ethical approval of this work done at the  
126 University of North Carolina at Chapel Hill, the Ponce de Leon/Emory University, and  
127 the University of Alabama at Birmingham. The Fenway Health Institutional Review  
128 Board of the Fenway Institute gave ethical approval of this work.

129

130 **Introduction**

131 Despite the proven effectiveness of behavioural and pharmacological methods of  
132 preventing HIV-1 (1-3), worldwide over 1.5 million individuals are estimated to acquire  
133 HIV yearly (4). Accordingly, long-acting and well-tolerated biomedical prevention  
134 approaches such as passive immunization using broadly neutralizing antibodies  
135 (bnAbs) are a promising new approach for HIV-1 prevention (5, 6). In the only efficacy  
136 trials of a bnAb against HIV-1 conducted to date, the Antibody Mediated Prevention  
137 (AMP) trials, overall efficacy was limited (7). Importantly however, the AMP studies  
138 provided proof of concept that passive immunization with a bnAb could confer protection  
139 against HIV-1 infection and identified neutralization as a correlate of protection (8).  
140 Despite overall low efficacy, viruses that were highly sensitive to neutralization by  
141 VRC01 ( $IC_{80} < 1 \mu\text{g/mL}$ ) were successfully blocked in vivo (7, 8). This result suggests  
142 that bnAbs with increased breadth and increased potency might provide increased  
143 protection.

144 Toward this aim, another antibody (VRC07) was identified from the same donor as  
145 VRC01, cloned, and then engineered to increase its neutralization potency and breadth  
146 (7). Additional mutations (Met428Leu and Asn434Ser; -LS) were made to the Fc portion  
147 of the antibody to increase the antibody's binding affinity for the neonatal Fc receptor  
148 (FcRn), resulting in increased recirculation and therefore a longer half-life in vivo (8, 9).  
149 The resultant antibody, VRC07-523LS, was 5-to 8-fold more potent than VRC01 and  
150 considerably broader in vitro, with an  $IC_{50} < 1 \mu\text{g/mL}$  against 92% of HIV-1  
151 pseudoviruses across circulating HIV-1 clades (7). In a first-in-human, dose-escalation  
152 study (VRC 605), VRC07-523LS administered intravenously (IV) to healthy volunteers

153 without HIV was safe, well-tolerated, and found to have a half-life of 38 days, more than  
154 twice the half-life of VRC01 (10).

155 The increased potency and durability of VRC07-523LS relative to VRC01 may help  
156 address a key question regarding bnAbs as a potential HIV prevention tool, namely the  
157 feasibility of their administration. More potent and longer-acting bnAbs can be  
158 administered less frequently and at lower doses and thus at lower cost. The route of  
159 administration is another important feasibility consideration, influenced by both dose  
160 and volume. In the AMP studies, the necessary dose and volume of the less potent  
161 VRC01 required IV administration. While IV administration was well-tolerated in the  
162 AMP studies, the World Health Organization (WHO)'s 2022 target product profile for  
163 HIV prevention bnAbs reflects a preference for subcutaneous (SC) or intramuscular (IM)  
164 injection, particularly for broad programmatic deployment in low and middle income  
165 countries (LMICs) (11).

166 In planning for an eventual efficacy trial with combination bnAb administration, we  
167 conducted a phase 1 study to comprehensively assess the safety and pharmacokinetics  
168 of VRC07-523LS at a range of doses and via several different routes of administration.

169

170



171 **Methods**

172 **Participants and Study Design**

173 HVTN 127/HPTN 087 is a multicenter, randomized, partially blinded phase 1 clinical trial  
174 to evaluate the safety and serum concentrations of VRC07-523LS, administered in  
175 multiple doses and routes to healthy adults without HIV (**Table 1**). Participants received  
176 five administrations of the assigned dose and route every four months at Weeks 0, 16,  
177 32, 48, and 64 and were followed on study through Week 112. The product was vialied  
178 at a concentration of 100 mg/mL and volume considerations limited the SC route to a  
179 maximum of 5 mg/kg and the IM route to 2.5 mg/kg.

180 Participants were enrolled at seven clinical research sites (CRSs): Brigham & Women's  
181 Hospital (Boston, MA), the Fenway Institute (Boston, MA), the University of North  
182 Carolina (Chapel Hill, NC), the University of Alabama (Birmingham, AL), Ponce de Leon  
183 CRS (Atlanta, GA), Columbia University (New York, NY), and the Centre Hospitalier  
184 Universitaire Vaudois (Lausanne, Switzerland). Volunteers were eligible if they were  
185 between 18 and 50 years of age, without HIV-1, in good overall health, and unlikely to  
186 acquire HIV during the study period based on behaviours reported within the 12 months  
187 prior to enrollment (12). The study was approved by the Institutional Review Boards of  
188 each participating CRS and all participants provided written informed consent. The HIV  
189 Vaccine Trials Network (HVTN) Safety Monitoring Board (SMB) provided safety  
190 oversight. The trial was registered with ClinicalTrials.gov (NCT03387150).

191 Participants were randomized through an Internet-based randomization system in  
192 blocks. Group 6 was added via an amendment after enrollment of Groups 1 to 5 began.

193 Participants and study staff were unblinded to group assignment (Groups 1 through 6)  
194 but blinded to antibody versus placebo within Group 6.

195

## 196 **Safety Assessments**

197 Following the first study product administration (SPA), participants were monitored for at  
198 least 60 minutes to assess for solicited local and systemic adverse events (AEs),  
199 including pain/tenderness at the infusion or injection site, fever, malaise, myalgia,  
200 headache, chills, arthralgia, nausea, urticaria, non-exertional dyspnea, non-exertional  
201 tachycardia, generalized pruritus, facial flushing, and unexplained diaphoresis. If no  
202 reactions occurred after the first administration, in-clinic monitoring after subsequent  
203 SPAs could decrease to 30 minutes. Participants completed daily symptom diaries to  
204 document solicited AEs for three days following each infusion or injection. Symptom-  
205 targeted physical exams and laboratory assays (complete blood count with differential,  
206 creatinine, alanine aminotransferase, urine dipstick, pregnancy testing, and HIV testing)  
207 were performed for safety monitoring at prespecified intervals throughout the study.  
208 Unsolicited AEs were collected throughout the study.

209

## 210 **Pharmacokinetics Studies**

### 211 *Enzyme Linked Immunosorbent Assay (ELISA)*

212 An ELISA assay was used to measure serum concentrations of VRC07-523LS between  
213 the first and second SPA. These concentrations were quantified in 96 well plates on a

214 Beckman Biomek based automation platform. The monoclonal antibody (mAb) 5C9 was  
215 coated onto Immulon-4HXB microtitre plates overnight at 4°C. Plates were then washed  
216 and blocked (10% FBS in PBS) for 2 hours at room temperature. Duplicate serial 3-fold  
217 dilutions covering the range of 1:100 – 1:24 300 of the test sample were incubated 2  
218 hours at 37°C followed by Horseradish Peroxidase (HRP) – labeled goat anti-human  
219 antibody (1 hour at 37°C) and TMB substrate (15 minutes at room temperature). Color  
220 development was stopped by addition of sulfuric acid and plates were read within 30  
221 minutes at 450 nm via the Molecular Devices Paradigm plate reader. Linear regression  
222 of a standard curve of VRC07-523LS covering the range from 0.91 to 5 ng/mL was  
223 utilized to quantitate sample concentrations based upon the average of sample dilutions  
224 within the range of the assay. The lower limit of quantification (LLoQ) of the ELISA  
225 assay was 1 µg/mL. Serum concentration data from 121 volunteers were measured by  
226 the ELISA assay on Target Visit Days 0, 3, 6, 28, 56, 84, and 112 (second SPA).

227

#### 228 *Binding Antibody Multiplex Array (BAMA)*

229 For programmatic reasons, the BAMA assay was used to measure serum  
230 concentrations of VRC07-523LS in samples collected after the second SPA in a subset  
231 of participants enrolled in each treatment group. Serum VRC07-523LS concentrations  
232 were measured on a Bio-Plex instrument (Bio-Rad) using a validated assay designed to  
233 measure infused VRC07-523LS by its ability to bind anti-idiotypic antibody captured on  
234 fluorescent magnetic beads. This assay was derived from a standardized custom HIV-1  
235 Luminex assay (13-16). The Bioplex software provides 2 readouts: a background-  
236 subtracted median fluorescent intensity (MFI), where background refers to a plate level

237 control (i.e., a blank well containing antigen-conjugated beads run on each plate), and a  
238 concentration based on a standard curve using a 5PL curve fit. Each sample was run in  
239 duplicate.

240 VRC07-523LS was titrated and combined to create a standard curve used to determine  
241 concentration of the diluted samples. The negative controls were CH58 (an irrelevant  
242 mAb) and blank beads. Samples with VRC07-523LS concentrations below 0.01 µg/mL  
243 at a dilution of 1:100 were truncated at 0.01 µg/mL for plotting purposes. All samples  
244 are shown in the plot, including concentrations below the LLoQ. Samples with  
245 concentrations above the LLoQ at a 1:100 dilution were further tested at various dilution  
246 factors to obtain MFIs in the linear range of the standard curve, and the in-well  
247 concentration closest to the  $EC_{50}$  of the 5PL standard curve was reported.

248 Several criteria were used to determine if data from an assay were acceptable and  
249 could be statistically analyzed. The standard curve  $EC_{50}$  values and MFI values were  
250 tracked against historical data in Levey Jennings and points with an MFI > 100 must  
251 have had a %CV <20% between replicates. Any sample without at least 2 observed  
252 concentrations in agreement with each other, or with baseline MFI > 1000 was repeated  
253 to obtain an accurate measurement. The physiological LLoQ of the BAMA assay was  
254 0.0457 µg/mL. Serum concentrations were measured using BAMA in 60 of 121  
255 participants who received the study product (10 randomly selected participants for each  
256 treatment group) in samples collected at target visit days 168, 224, 280, 336, 392, 448,  
257 504, 560, 616, 672, 728, 784.

258

259 *Neutralization activity*

260 Neutralizing antibody activity against HIV-1 was measured as a function of reduction in  
261 Tat-regulated luciferase (Luc) reporter gene expression in TZM-bl cells as described  
262 (17, 18). The assay performed in TZM-bl cells measured neutralization titres against  
263 Env-pseudotyped viruses sensitive to the bnAb (i.e., bnAb-specific viruses) in each  
264 group and a magnitude-breadth panel of Env-pseudotyped viruses. The assay tested  
265 neutralization of a panel of Tier 2 viruses that exhibit a range of known sensitivities to  
266 VRC07-523LS (**Supplemental Table 1**), which are H703\_0646\_051sN,  
267 H703\_1471\_190s, H703\_1750\_140Es, H704\_0726\_080sN, H704\_1535\_030sN,  
268 H704\_2544\_140eN01, PVO.4 (19), and a negative control Env-pseudotyped virus  
269 (SVA-MLV). Serum neutralization titre was defined as the serum dilution that reduced  
270 relative luminescence units (RLU) by 50% and 80% (ID<sub>50</sub> and ID<sub>80</sub>) relative to the RLU  
271 in virus control wells (cells + virus only) after subtraction of background RLU (cells only).

272

273 **Anti-Drug Antibodies**

274 Anti-drug antibodies (ADA) were assayed and characterized using a tiered bridging  
275 assay testing strategy, in which ADAs act to bridge labeled drug product and are  
276 detected in an electrochemiluminescent assay, as previously described (20). In Tier I, a  
277 sensitive binding assay determined if samples may have ADA present. In Tier II, the  
278 response was confirmed by establishing the specificity of the response by competition  
279 with free drug. In Tier III, the ADA response magnitude was characterized by titration.

280

## 281 **Statistical Methods**

### 282 *Endpoints*

283 The first primary endpoint was the safety and tolerability of different doses of VRC07-  
284 523LS administered IV, SC, and IM by repeat dosing every 16 weeks for a total of 5  
285 administrations. The second primary endpoint was the serum concentrations of VRC07-  
286 523LS administered IV, SC, and IM over 6 different dose/route regimens. The safety  
287 data analyses included data from all enrolled participants; the concentration data  
288 analyses included data from 121 participants who received VRC07-523LS (data from  
289 the three placebo recipients were excluded).

290

### 291 *Statistical approaches*

292 Magnitude-breadth (MB) curves (21) were constructed by study week for  $ID_{50}$  and  $ID_{80}$   
293 separately. All statistical analyses were carried out using R version 4.0.

294

### 295 *Population Pharmacokinetics Analysis*

296 The population pharmacokinetic (PK) profile of VRC07-523LS in serum was described  
297 using compartmental models. The analysis considered and compared PK models with  
298 one, two, and three compartments. These candidate models were fitted to observed  
299 serum concentrations using a nonlinear mixed effects approach, including random  
300 effects to account for inter-participant variability in PK parameters. The conditional  
301 variance of the error term, given the random effects, was assumed to include two

302 additive terms: one term was proportional to the conditional expectation of the  
303 concentration; the second term was a constant. Participant-specific (individual) PK  
304 parameters were assumed to follow log-normal distributions. The variance-covariance  
305 matrix of the random effects was fully unstructured. Additionally, PK parameters were  
306 adjusted for the assay (ELISA or BAMA) used to measure concentrations. The model  
307 was fitted using the method of maximum likelihood, implemented using the Stochastic  
308 Approximation Expectation Maximization (SAEM) algorithm. The significance of the  
309 difference in each PK parameter between the two assays was evaluated using Wald  
310 tests. Comparison of models with one, two, and three compartments was carried out  
311 using a corrected Bayes Information Criterion (BICc). Participant-specific PK  
312 parameters were predicted using their empirical Bayes estimates, defined as the most  
313 probable value of the participant-specific PK parameters, given the estimated population  
314 parameters and the data from the corresponding participant. These participant-specific  
315 PK parameters were used to predict the most probable trajectory of the serum  
316 concentration for each participant. Modeling assumptions were evaluated using  
317 weighted conditional residuals plotted as a function of study day. Model-based predicted  
318 participant-specific (most probable) serum concentration trajectories were plotted as a  
319 function of study day and compared to the observed serum concentrations. All  
320 compartmental PK analyses were conducted using MonolixSuite Version 2019R2 (22).  
321 The area under the curve (AUC) of the VRC07-523LS serum concentration of each  
322 individual study participant after one study product administration was computed by  
323 summing the estimate of the AUC between Days 0 and 112 computed using the  
324 trapezoidal method applied to untransformed serum concentrations and the estimate of

325 the AUC after Day 112 computed as  $\exp(a+112*b)/\exp(b)$  where a and b are the  
326 intercept and slope of a linear regression model describing log-serum concentration as  
327 a function of time since baseline and fitted to serum concentrations measured in the log-  
328 linear portion of the pharmacokinetics of VRC07-523LS.

329

### 330 *Neutralization Activity*

331 Key secondary objectives included determining whether serum neutralizing activity is  
332 maintained at consistent levels after each product administration and to determine  
333 whether serum neutralizing activity agreed with measured serum concentrations. A  
334 response to a given pseudovirus was considered positive if the corresponding ID<sub>50</sub> or  
335 ID<sub>80</sub> value was > 10 or 20, depending on the starting dilution of the sample. The assay  
336 measured neutralisation titres against seven Env-pseudotyped viruses to determine  
337 bnAbs activities against specific viruses (**Supplemental Table 1**).

338

339



## 340 **Results**

### 341 **Participant Characteristics and Demographics**

342 Participants were recruited between 02 February 2018 and 09 October 2018. A total of  
343 124 participants enrolled between 28 February 2018 and 09 October 2018 at six sites in  
344 the US and one in Switzerland (**Figure 1**). 75 participants (60%) were assigned female  
345 sex at birth; seven participants reported that they were gender non-conforming. 71  
346 participants (57%) identified as White, 28 (23%) as Black/African American, and 12  
347 (10%) as Hispanic (**Table 2**). The median age of participants at enrollment was 28  
348 years. Ninety-five participants (77%) received all five injections or infusions. The final  
349 SPA occurred on 10 January 2020, prior to the arrival of COVID-19 in the US or  
350 Switzerland, however pandemic restrictions had a considerable impact on follow-up  
351 visits. To ensure that sites could collect safety information, remote visits were permitted  
352 to be conducted, but no samples could be collected until local safety restrictions allowed  
353 in-person visits. The final study visit occurred on 04 December 2020. Sample availability  
354 is shown in **Figure 1**.

355

### 356 **Safety and Tolerability**

357 VRC07-523LS was safe and generally well-tolerated at all doses and via all routes  
358 administered (**Figure 2**). Mild to moderate injection site pain and/or tenderness was  
359 noted by most participants randomized to receive VRC07-523LS by the SC or IM  
360 routes. Erythema and/or induration at the injection site was noted by most participants

361 in the SC groups but was generally mild to moderate. Malaise/fatigue and headaches  
362 were the most common systemic solicited AEs.

363 The majority (98 [79%]) of participants experienced at least one AE during the study,  
364 but the vast majority were deemed unrelated to VRC07-523LS administration. Of the  
365 sixteen unsolicited AEs deemed related to VRC07-523LS, four began as solicited AEs  
366 that continued past the diary period and nine (7% of participants) were isolated  
367 symptoms or combinations of symptoms suggestive of infusion-related reactions, similar  
368 to those seen with VRC01 administration (23). These symptoms included generalized  
369 pruritis, facial flushing, chills, myalgia, arthralgia, nausea, headache, and diaphoresis.  
370 In three participants in the 20 mg/kg IV group, these combinations of symptoms were  
371 deemed to be consistent with infusion reactions. No pregnancies or HIV acquisitions  
372 were reported during the study. There were three serious adverse events (SAEs) all  
373 deemed unrelated to VRC07-523LS: *Staphylococcal* infection, pyrexia in a returned  
374 traveller, and urinary calculus.

375 Participants completed acceptability surveys at every SPA visit to assess their opinions  
376 on elements of the administration including discomfort, overall time commitment, and  
377 willingness to receive products via their specific route (**Supplemental Table 2**). In  
378 general, participants reported that the discomfort, pain, and anxiety related to the SPA  
379 was acceptable, although participants in the two SC groups were more likely to say that  
380 these were unacceptable (**Supplemental Tables 2A-2C**). The time required for SPA  
381 was considered acceptable by most participants (>87% across all visits and groups;  
382 **Supplemental Table 2D**). Most participants were very or somewhat willing to use the  
383 same method to prevent a serious illness (**Supplemental Table 2E**) and most would

384 recommend that method to a friend at risk of HIV, but this recommendation was lowest  
385 for participants in the SC groups at the final SPA (77.4% yes; **Supplemental Table 2F**).  
386 Four participants reported adverse social impacts (12) as a result of their participation,  
387 mostly in the realm of their interpersonal relationships.

388

### 389 **Anti-drug Antibody**

390 The presence and magnitude of ADA in serum were measured using a tiered “bridging  
391 assay” to detect ADA from serum samples obtained at Months 0, 2, 4, 8, and 16. A total  
392 of 124 participant samples were tested from Month 0, 1 from Month 2, 2 from Month 4,  
393 114 from Month 8 and 96 from Month 16. A single participant enrolled in Group 4 (SC  
394 route, 2.5 mg/kg VRC07-523LS) exhibited a confirmed ADA response at Month 8 (4  
395 months after the 2<sup>nd</sup> SPA) with a low titre of 1:9 but was ADA negative at Month 16 (4  
396 months after the 4<sup>th</sup> SPA).

397

### 398 **Serum Concentrations**

399 At a given dose, peak and trough concentrations were highest in the IV groups and  
400 lowest in the SC groups. Peak geometric mean titres (GMT) after the first dose, as  
401 measured by ELISA, were noted on Day 3, with GMT (95% CI) of 28.98 µg/mL (25.16,  
402 33.39) in the 2.5 mg/kg IV group, 58.51 µg/mL (49.41, 69.29) in the 5 mg/kg IV group,  
403 257.22 µg/mL (127.52, 518.86) in the 20 mg/kg IV group, 10.84 µg/mL (8.84, 13.3) in  
404 the 2.5 mg/kg SC group, 22.78 µg/mL (20.05, 25.88) in the 5 mg/kg SC group, and

405 16.35 µg/mL (14.71, 18.18) in the 2.5 mg/kg IM group (**Figure 3; Supplemental Figure**  
406 **1**). The lowest pre-administration troughs were noted on Day 112, just before the  
407 second infusion, with GMT (95% CI) of 3.4 µg/mL (2.51, 4.61) in the 2.5 mg/kg IV group,  
408 6.5 µg/mL (5.6, 7.54) in the 5 mg/kg IV group, 27.2 µg/mL (23.85, 31.01) in the 20  
409 mg/kg IV group, 0.97 µg/mL (0.65, 1.44) in the 2.5 mg/kg SC group, 3.09 µg/mL (2.2,  
410 4.33) in the 5 mg/kg SC group, and 2.61 µg/mL (2.05, 3.31) in the 2.5 mg/kg IM group  
411 (**Figure 3; Supplemental Figure 1**).

412 We compared the area under the curve (AUC) of the VRC07-523LS levels for the  
413 various doses and routes following the first administration. As a measure of exposure to  
414 VRC07-523LS, the AUC was higher in the 20 mg/kg IV group (**Supplemental Figure**  
415 **2A**). When corrected for the administered dose, the three IV groups had higher AUCs  
416 than either the SC or the IM groups (**Supplemental Figure 2B**), reflecting the lower  
417 bioavailability of the SC and IM routes.

418 The subsequent four-month post-administration troughs were slightly higher than after  
419 the first dose and quite similar between the second and fifth study product  
420 administrations (**Figure 4; Supplemental Figure 3**). This result suggests that there was  
421 very little in vivo accumulation of VRC07-523LS with the 16-weekly administration  
422 schedule, at least up to five consecutive doses. Furthermore, the relatively consistent  
423 levels of VRC07-523LS measured between the second and fifth administrations given at  
424 a frequency of four months suggests that a near steady state is established after the  
425 second administration with peaks and troughs determined by the dose and route.

426

## 427 **Population PK Analysis**

428 We conducted a population PK analysis of VRC07-523LS serum concentrations  
429 measured in healthy participants after up to five SPA via the IV, SC, or IM routes at  
430 various doses. Data were collected at 19 timepoints between Day 0 and Day 784,  
431 covering the period from baseline up to after the fifth SPA. The BICc determined that  
432 the two-compartment PK model was better at describing serum concentrations of  
433 VRC07-523LS than PK models with one or three compartments. The two-compartment  
434 PK model predicted well serum concentrations across routes of administration and  
435 doses (**Figure 5; Supplemental Figures 4A-F**). Estimated PK parameters are  
436 summarized in **Supplemental Table 3**.

437 Based on data measured between the first and second SPA using ELISA, the  
438 elimination half-life of VRC07-523LS was estimated as 42.43 days (SE = 0.75). Its  
439 bioavailability was estimated as 0.40 (SE = 0.0013) after SC administration, and 0.57  
440 (SE = 0.03) after IM administration, as compared with IV administration. The difference  
441 between the bioavailability after SC and IM administrations was significant ( $p < 0.001$ ).  
442 The average clearance of VRC07-523LS was 0.11 L/d (SE = 0.0031).

443 The analyses of serum concentrations measured after the first SPA using ELISA versus  
444 after the second SPA using BAMA found significantly different PK parameters, namely  
445 estimated clearance (0.15 L/d versus 0.11 L/d;  $p < 0.001$ ), central compartmental  
446 volume (3.18 versus 2.72,  $p < 0.001$ ), peripheral compartmental volume (3.74 versus  
447 3.59,  $p < 0.001$ ), and inter-compartmental clearance (1.18 L/day versus 0.49 L/day;  $p <$   
448  $0.001$ ). The distribution and elimination half-lives were also significantly different (4.61  
449 days versus 1.17 days,  $p < 0.001$ ; and 42.67 days versus 42.43 days,  $p < 0.001$ )

450 following the first SPA (by ELISA) and following the second SPA (by BAMA),  
451 respectively (**Supplemental Figure 5**). Although these differences are statistically  
452 significant, the absolute difference is quite small and unlikely to be clinically significant.  
453 Differences between the bioavailability and absorption rate constant based on BAMA  
454 versus ELISA derived data could not be estimated due to numerical instability occurring  
455 when fitting a population PK model that allowed for differences in these parameters  
456 between the two assays. This instability may be due to the differences in sampling  
457 frequency between the first and second SPA versus the less frequent sampling  
458 following the second SPA.

459 The analysis suggested that serum concentrations of VRC07-523LS increased linearly  
460 with the dose following IV and SC administrations, as evidenced by the population PK  
461 model properly fitting data across dose levels and routes of administration (**Figure 5**;  
462 **Supplemental Figures 4A-F**) and the similarity of the peak and trough levels as well as  
463 dose-normalized AUC across dose groups within a given route of administration  
464 (**Supplemental Figures 1 and 2**).

465

## 466 **Neutralization Activity**

467 Neutralization activity was assayed at 3 time points (Weeks 8, 72, and 88 following the  
468 first infusion of study product) in a subset of approximately 10 participants in each active  
469 treatment group and 3 placebo recipients, as follows: 9 participants in Group 1, 10 in  
470 Group 2, 10 in Group 3, 10 in Group 4, 10 in Group 5, 11 in Group 6, and 3 in the  
471 Placebo group.

472 In the IV and SC groups, response magnitudes increased overall with dose at a given  
473 timepoint (**Figure 6; Supplemental Figure 6**). Overall, response rates and magnitudes  
474 at Week 72 (8 weeks after the fifth study product administration) were either  
475 comparable to or slightly higher than those measured at Week 8 (8 weeks after the first  
476 study product administration), again suggesting limited accumulation of VRC07-523LS  
477 between the first and fifth administrations. As expected, the lowest response rates and  
478 magnitudes were observed at Week 88 (24 weeks after the fifth study product  
479 administration).

480 In addition to confirming that neutralization activity of VRC07-523LS is preserved  
481 following in vivo administration, these results allow us to compare the established in  
482 vitro ID<sub>80</sub> titre with the in vivo concentration to generate a predicted protective efficacy  
483 titre (PT<sub>80</sub>) (35). If an in vivo neutralization threshold of 200 is required for achieving  
484 potent prevention efficacy for VRC07-523LS (35), this level would only have been  
485 achieved for three of the primary HIV-1 isolates we tested even at 8 weeks after SPA  
486 (**Figure 6**).

487 At a given dose, higher serum neutralization titres were observed after IV  
488 administrations compared to either SC or IM administrations and this was particularly  
489 pronounced in the Magnitude-Breadth Area Under the Curve (MB-AUC) analysis  
490 (**Figure 7; Supplemental Figure 7**). The MB-AUC plots also indicate that neutralization  
491 activity was higher after receiving 5.0 mg/kg of VRC07-523LS via the SC route versus a  
492 lower dose of 2.5 mg/kg of VRC07-523LS via the IV route, suggesting that the levels of  
493 neutralization achieved by IV infusions may be reached by administering higher doses  
494 via the SC route. For the 2.5 mg/kg dose, which was the only one given via all three

495 routes, the neutralization titres were highest for the IV route, followed by the IM route,  
496 and lowest via the SC route. As with the neutralization titres, response rates tended to  
497 be higher in the IV groups than in the SC or IM groups when comparing responses  
498 among groups that received the same dose.

499

500



501 **Discussion**

502 This phase 1 clinical trial highlights several key findings which have implications for the  
503 design of future bnAb efficacy studies. First, a human neutralizing antibody engineered  
504 for breadth, potency, and a prolonged in vivo half-life was safe and generally well-  
505 tolerated when administered across a wide dose range and via different routes of  
506 administration. Second, although the half-life of this engineered bnAb is considerably  
507 longer than that of the VRC01 antibody used in the AMP studies (24), the half-life of  
508 VRC07-523LS is substantially less than VRC01LS (25). Third, while SC and IM  
509 administration of VRC07-523LS was safe and well-tolerated and these routes have  
510 notable operational advantages (11), decreased bioavailability may have implications  
511 for achieving target concentrations, and inter-individual variability in PK parameters  
512 observed must be considered in designing a combination bnAb efficacy study with  
513 VRC07-523LS.

514 In this study, we found that the serum concentrations of VRC07-523LS increased  
515 linearly across the dose range administered in this study. We also found that the peak  
516 and trough concentrations were highest in the IV groups and lowest in the SC groups at  
517 any given dose. There was also no significant difference in the half-life of VRC07-523LS  
518 when administered by different routes. These trends were also true for VRC01 and  
519 VRC01LS in other studies (25, 26), as well as for other bnAbs (27), which likely reflects  
520 generalizable PK behavior of antiviral antibodies in unexposed hosts. Some studies  
521 noted shorter half-lives of anti-HIV-1 bnAbs in persons living with HIV (28-30), which  
522 has implications for use of these biologics in HIV treatment and cure studies.

523 We also found an excellent correlation between the predicted level of VRC07-523LS  
524 and the measured serum concentrations, suggesting that a two-compartment model can  
525 predict the PK of this monoclonal antibody following repeated IV, SC, or IM  
526 administrations. This correlation was robust to dose, delivery route, and method of  
527 antibody measurement (ELISA vs BAMA). The high performance of these prediction  
528 models may allow future phase 1 studies to be smaller and more efficient, in terms of  
529 the number of participants needed, the number of injections or infusions administered,  
530 and the total length of follow-up needed to develop a robust PK model. This finding in  
531 turn has the potential to facilitate moving bnAbs into efficacy studies.

532 Data from this study has informed ongoing studies of combination bnAbs as it is likely  
533 that combinations of bnAbs targeting complementary epitopes on Env will be necessary  
534 to provide sufficient protection in vivo (6). VRC07-523LS has been evaluated in  
535 combination with the non-LS-mutated bnAbs PGT121, PGDM1400, and 10-1074, in the  
536 HVTN 130/HPTN 089 study (31). PGT121 and 10-1074 target the V3 glycan epitope  
537 whereas PGDM1400 targets the V1V2 region, and all three, while narrower in breadth  
538 than VRC07-523LS, are considerably more potent (32). As bnAbs with longer half-lives  
539 are likely to be more feasible for deployment (5, 6), VRC07-523LS is also being  
540 evaluated in combination with an engineered version of PGT121 called PGT121.414.LS  
541 in the recently completed HVTN 136/HPTN 092 trial [NCT04212091]. In the HVTN  
542 140/HPTN 101 study [NCT05184452], VRC07-523LS and PGT121.414.LS were tested  
543 in combination with PGDM1400LS. In the multi-phase CAPRISA 012 studies (33, 34),  
544 VRC07-523LS was tested with CAP256V2LS, a V1V2 targeting bnAb which is  
545 particularly potent against clade C isolates of HIV-1. Some of these studies include

546 modified SC administration methods (for example, SC infusion via pump in HVTN  
547 136/HPTN 092 [NCT04212091] and co-administration of bnAbs with hyaluronidase in  
548 CAPRISA 012 (33, 34)) to try to increase the bioavailability of the SC route.  
549 Furthermore, analysis of mucosal tissue and secretion PK of VRC07-523LS at rectal  
550 and vaginal sites is ongoing in the HVTN 128 trial [NCT03735849], which is particularly  
551 relevant as the vast majority of HIV-1 infections occur at mucosal sites.

552 Recently, the correlates of risk analyses from the AMP studies were used to generate a  
553 model of protective efficacy ( $PT_{80}$ ) that can be used for predicting efficacy of bnAbs  
554 against HIV-1 (35). The  $PT_{80}$  model combines in vitro  $IC_{80}$  neutralization data with in  
555 vivo PK data to provide an estimate of protection against a population of viruses to  
556 which participants may be exposed (35). This model was used to predict prevention  
557 efficacy (PE) of a hypothetical repeat of the AMP studies using the broader and more  
558 potent mAb VRC07-523LS as a single agent and suggested that PE in this case could  
559 have been approximately 79% against clade C viruses (35). However, the  $PT_{80}$  model  
560 also suggested that a high-dose three bnAb combination regimen including VRC07-  
561 523LS could have a PE of approximately 95% against a panel of recent clade C isolates  
562 (35). Ultimately, large efficacy studies will need to be performed with combination bnAbs  
563 to assess their ability to prevent HIV-1 acquisition.

564 UNAIDS recently released their preferred product characteristics (PPC) for mAbs for  
565 HIV-1 prevention, noting that longer-acting mAbs could play an important role in future  
566 pre-exposure prophylaxis (PrEP) campaigns as many people may opt for an injectable  
567 product rather than anti-retroviral pills or intra-vaginal rings (11). Long-acting prevention  
568 methods may be desirable for key populations such as pregnant women and adolescent

569 girls who are at high risk of HIV-1 acquisition, particularly in sub-Saharan Africa (11).  
570 While the UNAIDS PPC expressed a preference for SC administration, as noted for  
571 other low-volume mAbs for non-infectious indications (36), the participants in our SC  
572 groups had a somewhat less enthusiastic opinion about acceptability of SC  
573 administration compared to the other groups. Furthermore, the lower bioavailability  
574 observed for VRC07-523LS combined with the high concentrations likely needed to  
575 exceed the  $PT_{80}$  for circulating strains of HIV-1 argue that IV administration is more  
576 likely to be successful for HIV-1 prevention until the technical hurdles which impact  
577 injection volume and potency are overcome.

578

579 **Acknowledgments**

580 We wish to thank our volunteers for their generous participation in this study as well as  
581 the dedicated staff at the HVTN and HPTN clinical research sites and affiliated  
582 laboratories who made the study possible. We also wish to thank Mindy Miner and  
583 Nicole Na for editorial assistance as well as Jessica Fogel and Fatima Laher for their  
584 thoughtful comments on the manuscript.

585

586 The HVTN 127/HPTN 087 Study Group: In addition to the authors of this article,  
587 members of the HVTN 127/HPTN 087 Study Group consist of: Myron Cohen, Lawrence  
588 Corey, Jill Zeller, Gina Escamilla, Gail Broder, April Randhawa, Jessica Andriesen,  
589 Amanda Brown, Carter Bentley, Jontraye Davis, Huiyin Lu, Jignesh Patel, Tahereh  
590 Nourbakhsh, Shannon Grant, Rotrease Reagan, Jamel Young, Noshima Darden-Tabb,  
591 Jorge Benitez, Brett Gray, Joshua A. Weiner, Gabriela Kovacikova, Chanc E,  
592 VanWinkle Orzell, Maureen Furlong, Nathan Erdmann, Sonya Heath, Michel Obeid,  
593 Rosemary Hottinger, Rossi Fish, Adrianna Boulin, Gary Daffin, Marcy Gelman, Colleen  
594 Kelley, Jane A. Kleinjan, Jon A. Gothing, Elvin J. Fontana-Martinez, Michael S.  
595 Seaman, Raphael Dolin, and Jennifer A. Johnson.

596

597 **Figure Legends**

598 **Figure 1.** CONSORT diagram illustrating participant flow through the study.

599 **Figure 2.** Solicited adverse events (AEs) reported by participants after product  
600 administration. Local (A) and systemic (B) solicited AEs were collected for three days  
601 following each administration of VRC07-523LS or placebo. P6 = placebo IM; T1 = 2.5  
602 mg/kg IV; T2 = 5 mg/kg IV; T3 = 20 mg/kg IV; T4 = 2.5 mg/kg SC; T5 = 5 mg/kg SC; T6  
603 = 2.5 mg/kg IM.

604 **Figure 3.** VRC07–523LS serum concentration ( $\mu\text{g/mL}$ ) following first study product  
605 administration (SPA). Geometric means and 95% confidence intervals are presented,  
606 by treatment group and target day.

607 **Figure 4.** VRC07-523LS concentrations measured after product administration every  
608 four months at specified doses and routes. Peak levels were only assessed after the  
609 first dose. Levels following the second and subsequent doses were assessed by binding  
610 antigen multiplex assay (BAMA).

611 **Figure 5.** Measured serum concentrations of VRC07-523LS vs concentrations  
612 predicted by a two-compartment pharmacokinetic model.

613 **Figure 6.** Neutralization activity of participant serum following VRC07-523LS  
614 administration against seven HIV-1 isolates collected from incident HIV-1 acquisition  
615 events of placebo recipients in the AMP trials.  $\text{ID}_{80}$  titre is shown.

616 **Figure 7.** Magnitude-breadth curves for participant serum following VRC07-523LS  
617 administration against a panel of HIV-1 isolates collected from incident HIV-1 acquisition

618 of placebo recipients in the AMP trials. ID<sub>80</sub> titre is shown at Week 8 (A) and Week 72

619 (B).

620

621

## 622 References

623

- 624 1. Cohen MS, Gamble T, McCauley M. Prevention of HIV Transmission and the HPTN 052 Study.  
625 *Annu Rev Med.* 2020;71:347-60.
- 626 2. Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for  
627 the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. *Lancet.*  
628 2022;399(10337):1779-89.
- 629 3. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV  
630 Prevention in Cisgender Men and Transgender Women. *N Engl J Med.* 2021;385(7):595-608.
- 631 4. UNAIDS. Global HIV & AIDS statistics — Fact sheet [Available from:  
632 <https://www.unaids.org/en/resources/fact-sheet>.
- 633 5. Karuna ST, Corey L. Broadly Neutralizing Antibodies for HIV Prevention. *Annu Rev Med.*  
634 2020;71:329-46.
- 635 6. Walsh SR, Seaman MS. Broadly Neutralizing Antibodies for HIV-1 Prevention. *Front Immunol.*  
636 2021;12:712122.
- 637 7. Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, et al. Enhanced potency of a  
638 broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. *J*  
639 *Viro.* 2014;88(21):12669-82.
- 640 8. Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, Chen X, et al. Enhanced neonatal Fc receptor  
641 function improves protection against primate SHIV infection. *Nature.* 2014;514(7524):642-5.
- 642 9. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, et al. Enhanced antibody  
643 half-life improves in vivo activity. *Nat Biotechnol.* 2010;28(2):157-9.
- 644 10. Gaudinski MR, Houser KV, Doria-Rose NA, Chen GL, Rothwell RSS, Berkowitz N, et al. Safety and  
645 pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a  
646 phase 1 dose-escalation clinical trial. *Lancet HIV.* 2019;6(10):e667-e79.
- 647 11. WHO. WHO preferred product characteristics for monoclonal antibodies for HIV prevention  
648 [Available from: <https://www.who.int/publications/i/item/9789240045729>.
- 649 12. Andrasik MP, Sesay FA, Isaacs A, Oseso L, Allen M. Social Impacts Among Participants in HIV  
650 Vaccine Trial Network (HVTN) Preventive HIV Vaccine Trials. *J Acquir Immune Defic Syndr.*  
651 2020;84(5):488-96.
- 652 13. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-  
653 correlates analysis of an HIV-1 vaccine efficacy trial. *N Engl J Med.* 2012;366(14):1275-86.
- 654 14. Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, et al. Vaccine-induced plasma IgA  
655 specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. *Proc Natl*  
656 *Acad Sci U S A.* 2013;110(22):9019-24.
- 657 15. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, et al. Initial B-cell responses to  
658 transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG  
659 antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. *J Virol.*  
660 2008;82(24):12449-63.
- 661 16. Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, et al. Vaccine-induced Env  
662 V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. *Sci Transl*  
663 *Med.* 2014;6(228):228ra39.
- 664 17. Montefiori DC. Measuring HIV neutralization in a luciferase reporter gene assay. *Methods Mol*  
665 *Biol.* 2009;485:395-405.



- 666 18. Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilaska M, Greene KM, et al. Optimization and  
667 validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. *J*  
668 *Immunol Methods*. 2014;409:131-46.
- 669 19. Mkhize NN, Mapengo RE, Bekker V, Modise T, Kgagudi P, Lambson BE, et al., editors.  
670 Neutralization profiles of HIV-1 subtype C breakthrough viruses from the Southern African VRC01 AMP  
671 trial (HVTN 703/HPTN 081). *HIVR4P*; 2023; Virtual.
- 672 20. Bharadwaj P, Riekofski C, Lin S, Seaman MS, Garber DA, Montefiori D, et al. Implementation of a  
673 three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific  
674 broadly neutralizing antibodies. *J Immunol Methods*. 2020;479:112764.
- 675 21. Huang Y, Gilbert PB, Montefiori DC, Self SG. Simultaneous Evaluation of the Magnitude and  
676 Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine  
677 Development. *Stat Biopharm Res*. 2009;1(1):81-91.
- 678 22. Traynard P, Ayrat G, Twarogowska M, Chauvin J. Efficient Pharmacokinetic Modeling Workflow  
679 With the MonolixSuite: A Case Study of Remifentanyl. *CPT Pharmacometrics Syst Pharmacol*.  
680 2020;9(4):198-210.
- 681 23. Takuva S, Karuna ST, Juraska M, Rudnicki E, Edupuganti S, Anderson M, et al. Infusion Reactions  
682 After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results  
683 From the Phase 2b Antibody-Mediated Prevention Randomized Trials. *J Acquir Immune Defic Syndr*.  
684 2022;89(4):405-13.
- 685 24. Huang Y, Naidoo L, Zhang L, Carpp LN, Rudnicki E, Randhawa A, et al. Pharmacokinetics and  
686 predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated  
687 Prevention (AMP) trials. *EBioMedicine*. 2021;64:103203.
- 688 25. Gaudinski MR, Coates EE, Houser KV, Chen GL, Yamshchikov G, Saunders JG, et al. Safety and  
689 pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label  
690 clinical trial in healthy adults. *PLoS Med*. 2018;15(1):e1002493.
- 691 26. Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, et al. Safety, pharmacokinetics,  
692 and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal  
693 antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. *PLoS*  
694 *Med*. 2017;14(11):e1002435.
- 695 27. Cohen YZ, Butler AL, Millard K, Witmer-Pack M, Levin R, Unson-O'Brien C, et al. Safety,  
696 pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1  
697 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. *PLoS One*.  
698 2019;14(8):e0219142.
- 699 28. Stephenson KE, Julg B, Tan CS, Zash R, Walsh SR, Rolle CP, et al. Safety, pharmacokinetics and  
700 antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized,  
701 placebo-controlled, phase 1 clinical trial. *Nat Med*. 2021;27(10):1718-24.
- 702 29. Julg B, Stephenson KE, Wagh K, Tan SC, Zash R, Walsh S, et al. Safety and antiviral activity of  
703 triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical  
704 trial. *Nat Med*. 2022;28(6):1288-96.
- 705 30. Bar-On Y, Gruell H, Schoofs T, Pai JA, Nogueira L, Butler AL, et al. Safety and antiviral activity of  
706 combination HIV-1 broadly neutralizing antibodies in viremic individuals. *Nat Med*. 2018;24(11):1701-7.
- 707 31. Sobieszczyk ME, Mannheimer S, Paez CA, Yu C, Gamble T, Theodore DA, et al. Safety,  
708 tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations  
709 of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered  
710 intravenously to HIV-uninfected adults: a phase 1 randomised trial. *Lancet HIV*. 2023;10(10):e653-e62.
- 711 32. Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, et al. Optimal Combinations  
712 of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. *PLoS*  
713 *Pathog*. 2016;12(3):e1005520.

- 714 33. Mahomed S, Garrett N, Karim QA, Zuma NY, Capparelli E, Baxter C, et al. Assessing the safety  
715 and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with  
716 VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B  
717 phase I clinical trial. *BMJ Open*. 2020;10(11):e042247.
- 718 34. Mahomed S, Garrett N, Capparelli EV, Osman F, Mkhize NN, Harkoo I, et al. Safety and  
719 pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered  
720 with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-  
721 escalation, randomised controlled trial. *Lancet HIV*. 2023;10(4):e230-e43.
- 722 35. Gilbert PB, Huang Y, deCamp AC, Karuna S, Zhang Y, Magaret CA, et al. Neutralization titer  
723 biomarker for antibody-mediated prevention of HIV-1 acquisition. *Nat Med*. 2022;28(9):1924-32.
- 724 36. Melichar B, Studentova H, Kalabova H, Vitaskova D. Role of subcutaneous formulation of  
725 trastuzumab in the treatment of patients with HER2-positive breast cancer. *Immunotherapy*.  
726 2014;6(7):811-9.

727

728

729

730 **Table 1.** Study schema

731

Group	N	Dose	Route	Month 0	Month 4	Month 8	Month 12	Month 16
T1	19	2.5 mg/kg	IV	X	X	X	X	X
T2	19	5 mg/kg	IV	X	X	X	X	X
T3	21	20 mg/kg	IV	X	X	X	X	X
T4	21	2.5 mg/kg	SC	X	X	X	X	X
T5	20	5 mg/kg	SC	X	X	X	X	X
T6	21	2.5 mg/kg	IM	X	X	X	X	X
P6	3	Placebo	IM	X	X	X	X	X

732

733 IV – intravenous; SC – subcutaneous; IM – intramuscular

734

735

736 **Table 2.** Participant demographics  
737

	<b>Female</b>	<b>Male</b>	<b>Total</b>
Black or African-American	19	9	28 (23%)
Asian	3	3	6 (5%)
White	41	30	71 (57%)
Other	6	2	8 (7%)
Multi-racial	6	5	11 (9%)
Hispanic	7	5	12 (10%)
Non-Hispanic	68	44	112 (90%)
<b>Total</b>	<b>75 (60%)</b>	<b>49 (40%)</b>	<b>124</b>

738  
739  
740

Figure 1.

HVTN 127/HPTN 087






Figure 1. CONSORT diagram.

Figure 2

A




B



**Figure 2.** Solicited adverse events (AEs). Local (A) and systemic solicited AEs were collected for three days following each administration. P6 = placebo IM; T1 = 2.5 mg/kg IV; T2 = 5 mg/kg IV; T3 = 20 mg/kg IV; T4 = 2.5 mg/kg SC; T5 = 5 mg/kg SC; T6 = 2.5 mg/kg IM.

Figure 3.


HVTN 127/HPTN 087



**Figure 3:** VRC07-523LS serum concentration (µg/mL) following first study product administration (SPA). Geometric means and 95% confidence intervals are presented, by treatment group and target day.

Figure 4

HVTN 127/HPTN 087




**Figure 4.** VRC07-523LS concentrations measured after product administration every four months at specified doses and routes. Peak levels were only assessed after the first dose. Levels following the second and subsequent doses were assessed by binding antigen multiplex assay (BAMA).



Figure 5.


HVTN 127/HPTN 087



**Figure 5.** Measured serum concentrations of VRC07-523LS vs concentrations predicted by a two-compartment pharmacokinetic model.

Figure 6


HVTN 127/HPTN 087



**Figure 6.** Neutralization activity of participant serum 8 weeks following their first VRC07-523LS administration against seven HIV-1 isolates collected from incident HIV-1 acquisition events in placebo recipients in the AMP trials.  $ID_{80}$  titre is shown.

Figure 7

HVTN 127/HPTN 087



**Figure 7.** Magnitude-breadth curves for participant serum following VRC07-523LS administration against a panel of HIV-1 isolates collected from incident HIV-1 acquisition events in placebo recipients in the AMP trials. ID<sub>80</sub> titre is shown at Week 8 (**A**) and Week 72 (**B**).